semaglutide and cagrilintide Cagrilintide–semaglutide (CagriSema) versus or in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study CagriSema Dosage Protocol: Research Reference
Description
2013 Aug;10(2):203-10

At 1 mm per day, that may require up to 3 months before you will see the first movements

Key Research Findings: Cagrilintide has shown to reduce food intake and slow gastric emptying, mimicking the natural actions of amylin (Kapitza et al.)

Continue to protect from light and heat
